Minor
MAPKeeper 301 · Atebimetinib + GnP as a First Line Treatment · Metastatic Pancreatic Adenocarcinoma
Trial sites expanded: 57 → 63 locations
And 2 more changes in the last 30 days
Immuneering CorporationPhase 3 NCT07562152 Registry history of NCT07562152 on ClinicalTrials.gov (opens the registry)